Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

Journal Articles

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

Martin H Van Vliet, Yan-Ting Chen, PhD, Erik H Van Beers, PhD, Rowan Kuiper, PhD, Erik T. Valent, PhD, Marieke Spaan, MSc, Carolina Terragna, Elena Zamagni, Michele Cavo, Stefania Oliva, Alessandra Larocca, Torsten Haferlach, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Anders Waage, MD PhD, M Duin, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-137389

Published: 2020

Journal Articles

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Rowan Kuiper, PhD, Mark van Duin, PhD, Martin H Van Vliet, Erik H Van Beers, PhD, Berna Berna Beverloo, PhD, Sonja Zweegman, MD PhD, Tom Cupedo, PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139987

Published: 2020

Journal Articles

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Davine Hofste op Bruinink, MD MSc, Mark van Duin, PhD, Meral Beksac, MD, Christoph Driessen, MD, Heinz Ludwig, MD, Michael Vermeulen, BSc, Rowan Kuiper, MSc, Martin H van Vliet, PhD, Bronno van der Holt, PhD, Roman Hajek, MD PhD, Hans Erik Johnsen, MD Professor, Meletios A Dimopoulos, MD, Antonio Palumbo, MD, Michele Cavo, MD, Pieter Sonneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2018-99-119873

Published: 2018

Journal Articles

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

Erik H Van Beers, Carolina Terragna, Marina Martello, Elena Zamagni, MD, Michele Cavo, MD, Martin H van Vliet, PhD, Giovanni Martinelli, MD, Rowan Kuiper, MSc

Blood (2017) 130 (Supplement 1): 4358.

https://doi.org/10.1182/blood.V130.Suppl_1.4358.4358

Published: 2017

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights

Simone Weber, Marietta Truger, Wolfgang Kern, MD, Martin H van Vliet, PhD, Erik H van Beers, Niroshan Nadarajah, M.Sc., Manja Meggendorfer, PhD, Dennis Haupt, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2016) 128 (22): 4424.

https://doi.org/10.1182/blood.V128.22.4424.4424

Published: 2016

Journal Articles

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Rowan Kuiper, Mark van Duin, Martin H. van Vliet, Annemiek Broijl, Bronno van der Holt, Laila el Jarari, Erik H. van Beers, George Mulligan, Hervé Avet-Loiseau, Walter M. Gregory, Gareth Morgan, Hartmut Goldschmidt, Henk M. Lokhorst, Pieter Sonneveld

Blood (2015) 126 (17): 1996–2004.

https://doi.org/10.1182/blood-2015-05-644039

Published: 2015

Includes: Supplemental data

Journal Articles

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

Martin H. Van Vliet, PhD, Rowan Kuiper, BSc, Belinda Dumee, BSc, Leonie de Best, MSc, Peter J. van der Spek, PhD, Emmanuel M.E.H. Lesaffre, PhD, Mark van Duin, PhD, Anders Waage, MD PhD, Sonja Zweegman, MDPhD, Pieter Sonneveld, MDPhD, Erik H. van Beers, PhD

Blood (2014) 124 (21): 2026.

https://doi.org/10.1182/blood.V124.21.2026.2026

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray

Erik H van Beers, PhD, Jaap Brand, PhD, Martin H. van Vliet, PhD, Henk E Vietor, MD, PhD, Peter J. M. Valk, PhD, Bob Lowenberg, MD, PhD

Blood (2012) 120 (21): 1420.

https://doi.org/10.1182/blood.V120.21.1420.1420

Published: 2012

Journal Articles

A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients

Erik H. van Beers, PhD, Leonie de Best, Martin H. van Vliet, PhD, Jaap Brand, PhD, Pia Burgmer, Linda de Quartel, Belinda Dumee, Astrid Provoost, Peter Valk, Lars Bullinger, Peter J van der Spek, PhD, Henk E Vietor, MD, PhD, Hartmut Doehner, Prof. Dr. med., Bob Lowenberg, MD, PhD

Blood (2011) 118 (21): 4876.

https://doi.org/10.1182/blood.V118.21.4876.4876

Published: 2011

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Annemiek Broyl, MD, Rowan Kuiper, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Yvonne de Knegt, Bronno van der Holt, PhD, Laila el Jarari, Berna Beverloo, PhD, H. Lokhorst, Sonja Zweegman, George Mulligan, PhD, Hartmut Goldschmidt, Mark van Duin, PhD, Pieter Sonneveld

Blood (2010) 116 (21): 445.

https://doi.org/10.1182/blood.V116.21.445.445

Published: 2010

NARROW

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray

A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients

A High-Risk Survival Classifier for Multiple Myeloma

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only